select a format

Single User License
USD 125 INR 8023
Site License
USD 250 INR 16045
Corporate User License
USD 375 INR 24068

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


CTI BioPharma Corp (CTIC)-Financial and Strategic SWOT Analysis Review

CTI BioPharma Corp (CTIC)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH34546FSA
  • |
  • Pages: 51
  • |
  • April 2017
  • |
  • |
  Request for Sample Report

Executive Summary

CTI BioPharma Corp (CTIC)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company's lead product, Pixuvri (pixantrone) is an aza-anthracenedione that is used for the treatment of multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) in adults. Its pipeline portfolio consists of Pacritinib for the treatment of myelofibrosis for all platelet counts, relapsed acute myeloid leukemia (AML), other hematological and solid tumor indications; and Tosedostat for AML and myelodysplastic syndrome. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp Key Recent Developments

Mar 02,2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results

Feb 27,2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO

Jan 24,2017: CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors

Dec 01,2016: CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium

Nov 08,2016: CTI BioPharma Reports Third Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

CTI BioPharma Corp-Key Facts 6

CTI BioPharma Corp-Key Employees 7

CTI BioPharma Corp-Key Employee Biographies 8

CTI BioPharma Corp-Major Products and Services 10

CTI BioPharma Corp-Pharmaceutical Pipeline Products Data 11

CTI BioPharma Corp, Pipeline Products by Therapy Area 11

CTI BioPharma Corp, Pipeline Products by Development Phase 11

CTI BioPharma Corp-History 13

CTI BioPharma Corp-Company Statement 16

CTI BioPharma Corp-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Section 2-Company Analysis 19

CTI BioPharma Corp-Business Description 19

CTI BioPharma Corp-Corporate Strategy 20

CTI BioPharma Corp-SWOT Analysis 21

SWOT Analysis-Overview 21

CTI BioPharma Corp-Strengths 21

CTI BioPharma Corp-Weaknesses 22

CTI BioPharma Corp-Opportunities 23

CTI BioPharma Corp-Threats 24

CTI BioPharma Corp-Key Competitors 25

Section 3-Company Financial Ratios 26

Financial Ratios-Capital Market Ratios 26

Financial Ratios-Annual Ratios 27

Performance Chart 29

Financial Performance 29

Financial Ratios-Interim Ratios 30

Financial Ratios-Ratio Charts 31

Section 4-Company's Lifesciences Financial Deals and Alliances 32

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33

CTI BioPharma Corp, Recent Deals Summary 34

Section 5-Company's Recent Developments 35

Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 35

Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 37

Jan 24, 2017: CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors 38

Dec 01, 2016: CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 39

Nov 08, 2016: CTI BioPharma Reports Third Quarter 2016 Financial Results 40

Oct 03, 2016: CTI BioPharma Announces Retirement Of President And CEO 41

Aug 04, 2016: CTI BioPharma Reports Second Quarter 2016 Financial Results 42

May 10, 2016: CTI BioPharma Reports First Quarter 2016 Financial Results 43

Feb 16, 2016: CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results 44

Jan 13, 2016: CTI BioPharma Appoints Matthew Perry To Board Of Directors 46

Section 6-Appendix 47

Methodology 47

Ratio Definitions 47

About GlobalData 51

Contact Us 51

Disclaimer 51

List of Figures

CTI BioPharma Corp, Pipeline Products by Therapy Area 11

CTI BioPharma Corp, Pipeline Products by Development Phase 11

CTI BioPharma Corp, Performance Chart (2012-2016) 29

CTI BioPharma Corp, Ratio Charts 31

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 33

List of Tables

CTI BioPharma Corp, Key Facts 6

CTI BioPharma Corp, Key Employees 7

CTI BioPharma Corp, Key Employee Biographies 8

CTI BioPharma Corp, Major Products and Services 10

CTI BioPharma Corp, Number of Pipeline Products by Development Stage 12

CTI BioPharma Corp, History 13

CTI BioPharma Corp, Subsidiaries 18

CTI BioPharma Corp, Key Competitors 25

CTI BioPharma Corp, Ratios based on current share price 26

CTI BioPharma Corp, Annual Ratios 27

CTI BioPharma Corp, Annual Ratios (Cont...1) 28

CTI BioPharma Corp, Interim Ratios 30

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33

CTI BioPharma Corp, Recent Deals Summary 34

Currency Codes 47

Capital Market Ratios 47

Equity Ratios 48

Profitability Ratios 48

Cost Ratios 49

Liquidity Ratios 49

Leverage Ratios 50

Efficiency Ratios 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Puma Biotechnology Inc, Orexigen Therapeutics Inc, Oncogenex Pharmaceuticals Inc, Incyte Corp, Geron Corp, Clovis Oncology Inc, Array BioPharma Inc, Ariad Pharmaceuticals Inc


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com